asciminib

Active substance asciminib
Holder Novartis
Status Running
Indication Patients with chronic myeloid leukemia (CML) in chronic phase previously treated with ≥ 2 TKIs
Public documents Approbation
  Information for the patient
  Informed consent
Last update 11/08/2022

 

Last updated on 28/09/2022